Analyzing Tetralogic Pharmaceuticals Corp (TLOG) and Anavex Life Sciences Corp. (AVXL)
Tetralogic Pharmaceuticals Corp (NASDAQ: TLOG) and Anavex Life Sciences Corp. (NASDAQ:AVXL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, valuation, profitability, dividends, risk and analyst recommendations.
This table compares Tetralogic Pharmaceuticals Corp and Anavex Life Sciences Corp.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-73.81%|
|Anavex Life Sciences Corp.||N/A||-95.68%||-84.88%|
Institutional & Insider Ownership
2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. Comparatively, 24.4% of Anavex Life Sciences Corp. shares are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Comparatively, 11.6% of Anavex Life Sciences Corp. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Tetralogic Pharmaceuticals Corp and Anavex Life Sciences Corp.’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Tetralogic Pharmaceuticals Corp||N/A||N/A||-$21.14 million||($1.76)||-0.01|
|Anavex Life Sciences Corp.||N/A||N/A||-$15.61 million||($0.39)||-11.79|
Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals Corp, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Tetralogic Pharmaceuticals Corp and Anavex Life Sciences Corp., as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tetralogic Pharmaceuticals Corp||0||0||0||0||N/A|
|Anavex Life Sciences Corp.||0||0||3||0||3.00|
Anavex Life Sciences Corp. has a consensus price target of $13.67, indicating a potential upside of 197.10%. Given Anavex Life Sciences Corp.’s higher possible upside, analysts clearly believe Anavex Life Sciences Corp. is more favorable than Tetralogic Pharmaceuticals Corp.
Volatility & Risk
Tetralogic Pharmaceuticals Corp has a beta of 3, indicating that its share price is 200% more volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp. has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Anavex Life Sciences Corp. beats Tetralogic Pharmaceuticals Corp on 5 of the 9 factors compared between the two stocks.
Tetralogic Pharmaceuticals Corp Company Profile
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Anavex Life Sciences Corp. Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.
Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.